---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-273342"
form_type: "8-K"
ticker: "DMRA"
cik: "0001800315"
company_name: "Damora Therapeutics, Inc."
filed_at: "2025-11-10T23:59:59+00:00"
generated_at: "2026-05-16T22:32:36.041245+00:00"
event_type: "m_and_a"
sentiment: "neutral"
materiality_score: 0.9
calibrated_materiality_score: 0.9
confidence: "high"
source: SEC EDGAR
---

# Galecto acquires Damora, raises ~$285M PIPE, appoints Fairmount-affiliated directors

## Summary
- Galecto acquired Damora Therapeutics; issued 265,309 common shares, 16,366 Series B and 4,241 Series C preferred shares to Damora stockholders.
- Concurrent PIPE of ~$285M via sale of 39,641 Series C preferred shares; closing expected Nov 12, 2025.
- Board replaced: Anne Prener, David Shapiro, Amy Wechsler resigned; Peter Harwin, Chris Cain, Julianne Bruno (Fairmount) appointed.
- Executive retention bonuses: CEO (DKK 2,173,800 target), CFO ($112,500), GC ($161,160); CFO salary increased to $375,000.
- Series B & C preferred are non-voting, convertible 1:1,000 into common, subject to stockholder approval and ownership caps.

## SEC filing metadata
- accession: 0001193125-25-273342
- form_type: 8-K
- ticker: DMRA
- cik: 0001800315
- company_name: Damora Therapeutics, Inc.
- filed_at: 2025-11-10T23:59:59+00:00
- event_type: m_and_a
- sentiment: neutral
- materiality_score: 0.9
- calibrated_materiality_score: 0.9
- confidence: high
- sec_items: 1.01, 5.03, 2.01, 3.02, 5.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1800315/000119312525273342/0001193125-25-273342-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1800315/000119312525273342/d53983d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-273342
- JSON: https://secwatch.observer/filing/0001193125-25-273342.json
- Plain text: https://secwatch.observer/filing/0001193125-25-273342.txt

## Source-grounded claims
- claim_id: 9c5a682743c1eb233b78d9774894ed8438b2cbc4
  claim: Damora Therapeutics, Inc.: Filed Certificates of Designation for Series B and Series C Preferred Stock, creating new stock series with specific rights and limitations (effective 2025-11-07).
  evidence_excerpt: On November 7, 2025, the Company filed with the Secretary of State of the State of Delaware a Certificate of Designation of Preferences, Rights and Limitations of the Series B Preferred Stock (the “Certificate of Designation of Series B Preferred Stock”) and a Certificate of Designation of Preferences, Rights and Limitations of the Series C Preferred Stock (the “Certificate of Designation of Series C Preferred Stock,” and together with the Certificate of Designation of Series B Preferred Stock, the “Certificates of Designation”) in connection with the Merger and the Financing referenced in Item 1.01 above.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1800315/000119312525273342/0001193125-25-273342-index.htm
- claim_id: 80cb62a3192508a9b687b9b76da5ad3ff04de96e
  claim: Damora Therapeutics, Inc. completed an acquisition involving Damora Therapeutics, Inc. (closed 2025-11-10).
  evidence_excerpt: On November 10, 2025, the Company completed its business combination with Damora.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1800315/000119312525273342/0001193125-25-273342-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.